Beta Bionics Inc [BBNX] stock is trading at $20.2, up 0.50%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The BBNX shares have gain 7.96% over the last week, with a monthly amount glided 32.89%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Beta Bionics Inc [NASDAQ: BBNX] stock has seen the most recent analyst activity on June 16, 2025, when Truist initiated its Buy rating and assigned the stock a price target of $26. Previously, Lake Street started tracking the stock with Buy rating on June 12, 2025, and set its price target to $30. On May 30, 2025, Wolfe Research initiated with a Outperform rating and assigned a price target of $20 on the stock. Goldman started tracking the stock assigning a Neutral rating and suggested a price target of $16 on May 30, 2025. Stifel initiated its recommendation with a Buy and recommended $25 as its price target on February 24, 2025. Piper Sandler started tracking with a Overweight rating for this stock on February 24, 2025, and assigned it a price target of $26. In a note dated February 24, 2025, Leerink Partners initiated an Outperform rating and provided a target price of $28 on this stock.
Beta Bionics Inc [BBNX] stock has fluctuated between $8.89 and $24.50 over the past year. Currently, Wall Street analysts expect the stock to reach $17 within the next 12 months. Beta Bionics Inc [NASDAQ: BBNX] shares were valued at $20.2 at the most recent close of the market. An investor can expect a potential drop of -15.84% based on the average BBNX price forecast.
Analyzing the BBNX fundamentals
Beta Bionics Inc [NASDAQ:BBNX] reported sales of 78.02M for the trailing twelve months, which represents a growth of 54.45%. Gross Profit Margin for this corporation currently stands at 0.54% with Operating Profit Margin at -0.8%, Pretax Profit Margin comes in at -0.94%, and Net Profit Margin reading is -0.94%. To continue investigating profitability, this company’s Return on Assets is posted at -0.22, Equity is -0.41 and Total Capital is -0.2. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 19.69 points at the first support level, and at 19.18 for the second support level. However, for the 1st resistance point, the stock is sitting at 20.89, and for the 2nd resistance point, it is at 21.59.
Ratios To Look Out For
For context, Beta Bionics Inc’s Current Ratio is 14.68. As well, the Quick Ratio is 13.79, while the Cash Ratio is 1.8. Considering the valuation of this stock, the price to sales ratio is 11.25, the price to book ratio is 2.91.
Transactions by insiders
Recent insider trading involved Hopma Mark, Officer, that happened on Sep 05 ’25 when 11411.0 shares were purchased. Officer, Feider Stephen completed a deal on Sep 05 ’25 to buy 100.0 shares. Meanwhile, President & CEO Saint Sean sold 3359.0 shares on Sep 02 ’25.
